What makes UpToDate so powerful?

  • over 10,000 topics
  • 22 specialties
  • 5,700 physician authors
  • evidence-based recommendations
See more sample topics
Find Patient Print
0 Find synonyms

Find synonyms Find exact match

Management of infantile hemangiomas
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
Management of infantile hemangiomas
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jul 2016. | This topic last updated: May 18, 2016.

INTRODUCTION — Infantile hemangiomas are benign tumors of vascular endothelium [1,2]. They are the most common tumors of childhood. They are characterized by a growth phase and involution phase. Despite their benign and self-limited nature, some hemangiomas can cause complications such as ulceration or life-altering disfigurement. In addition, they may compromise vital organ function or herald underlying developmental anomalies of the central nervous system or spine. Infants with cutaneous hemangiomas, most often in the setting of multiple hemangiomas or a solitary segmental hemangioma, occasionally have additional hemangiomas of the liver, brain, respiratory tract, or gastrointestinal tract. Rarely, visceral hemangiomas can be symptomatic and associated with life-threatening complications.

The management of infantile hemangiomas will be discussed below. The epidemiology, pathogenesis, clinical features, complications, and evaluation are discussed separately. Other vascular tumors of childhood are also discussed separately.

(See "Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications".)

(See "Evaluation and diagnosis of infantile hemangiomas".)

(See "Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH) and noninvoluting congenital hemangioma (NICH)".)

(See "Tufted angioma, kaposiform hemangioendothelioma, and the Kasabach-Merritt phenomenon".)

GENERAL APPROACH — The approach to treatment of hemangiomas should be individualized, based upon the size of the lesion(s), morphology, location, presence or possibility of complications, potential for scarring or disfigurement, the age of the patient, and the rate of growth or involution at the time of evaluation [3,4]. The potential risk(s) of treatment must be carefully weighed against the potential benefits.

Consultation with and/or referral to a pediatric dermatologist, vascular anomalies team, or other knowledgeable specialist is warranted for children with hemangiomas with actual or potential risk for complications and/or when therapy is being considered [5]. Such children should be referred as early as possible during the early proliferation phase (ie, during the first few months of life).

Hemangiomas are managed with clinical examination(s) and education of the family regarding the natural course; potential complications; treatment indications; and risks, benefits, and expectations of available treatment options. Depending upon the type of lesion and the parents' level of concern, the patient may need to be re-evaluated frequently during the proliferative phase and again before school entry. Serial photographs of the lesion can help to monitor the clinical course.

Education of the family should include information about the natural course; potential complications; treatment indications; and risks, benefits, and expectations of available treatment options for hemangiomas. The family should be provided with realistic expectations about the duration of involution and the possibility of residual changes. It has been estimated that completed involution occurs at an average minimum rate of 10 percent per year, so approximately 50 percent of hemangiomas have involuted by age five years, 70 percent by age seven, and 90 percent by age nine [6]. However, this timeline is highly variable and dependent on hemangioma size, morphology, and location. It must also be emphasized that, in many cases, involution does not result in normal-appearing skin. Nearly one-half of children with untreated hemangiomas experience residual changes such as scarring, atrophy, redundant skin, discoloration, and telangiectasias.

Finally, the family should be provided with anticipatory guidance regarding ways to respond to comments and queries from family members and strangers. Parents are commonly subject to inappropriate comments from strangers, including accusations of child abuse [7]. Other children, who are usually extremely curious about the hemangioma, are often satisfied to know simply that "It is a birthmark, it doesn't hurt, and it will get better" [7]. Addressing the psychosocial aspects of care and providing the parents anticipatory guidance, emotional support, and reassurance are essential for the effective management of hemangiomas [3,7-9].

When treatment is indicated, the choice of treatment modality depends upon the above factors, as well as the availability of certain modalities and the experience of the treating clinician.

INDICATIONS FOR INTERVENTION AND GOALS OF TREATMENT — Intervention may be required for complicated lesions with potential to interfere with a vital structure or function. These include, but are not limited to [5]:

Very large, rapidly growing cutaneous hemangiomas

Lesions in the periorbital region

Lesions in the airway, liver, or gastrointestinal tract

In addition, intervention may be indicated for lesions associated with other complications such as ulceration and/or increased risk of scarring or disfigurement:

Large, plaque-like (segmental) or nodular hemangiomas, especially in trauma-prone locations, have a tendency toward ulceration, which invariably leads to scarring.

Any lesion of the face, especially when large or segmental; hemangiomas of the lip (picture 1), nose ("Cyrano nose"), and auricle are particularly prone to disfigurement.

Large, nodular, superficial hemangiomas, especially those that exhibit a sharp, "cliff-like" border (picture 2), or pedunculated lesions (hemangiomas extending from a small base) have the greatest risk of scarring. These lesions are also at risk for leaving residual fibrofatty tissue that may require surgical revision.

The goals of hemangioma treatment include [3]:

Prevention or reversal of life-threatening or function-threatening complications

Prevention or minimization of disfigurement from residual skin changes

Minimization of psychosocial distress for the patient and family

Adequate treatment of ulceration to minimize scarring, bleeding, infection, and pain


Active nonintervention — Active nonintervention is the mainstay of therapy for many uncomplicated, localized hemangiomas because hemangiomas involute spontaneously after the first year of life. However, the decision not to pursue medical and surgical therapy is not necessarily a passive intervention, since the growth and involution of the hemangioma may need to be monitored and the psychosocial implications, particularly of facial hemangiomas, anticipated and addressed [7]. Serial photographs of the lesion may be helpful to monitor the involution process and outcome.

Local therapies — Local pharmacotherapy is primarily used in the treatment of small or superficial infantile hemangiomas and is not indicated for the treatment of complicated lesions. Data on the efficacy of topical therapies, including topical beta blockers, corticosteroids, and imiquimod, are limited.  

Topical beta blockers — Reports of successful treatment of hemangiomas with systemic propranolol led to the investigation of topical beta blocker therapy for the treatment of infantile hemangiomas [10,11]. Topical beta blockers may be used for the treatment of small superficial hemangiomas (eg, hemangiomas of minor cosmetic concern located on the face, small lesions in the anogenital area) as an alternative to observation, particularly if parents desire treatment. Topical beta blockers may also have a role in the treatment of small ulcerated hemangiomas and in preventing rebound growth in children who are being tapered off oral propranolol [12]. (See 'Rebound growth' below and 'Ulcerated hemangiomas' below.)

If a decision is made to use topical beta blockers, we use topical (ophthalmic) timolol gel-forming solution 0.5% two or three times per day for 6 to 12 weeks or until stable improvement is achieved. If no response is seen after the first four to six weeks, treatment should be discontinued.

The efficacy of topical propranolol 1% or topical timolol 0.5% has been confirmed by a 2015 systematic review and meta-analysis of 14 cohort studies and three randomized trials [13]. In this analysis, the pooled response rate was approximately 80 percent for both topical propranolol and topical timolol.

Topical and intralesional corticosteroids — High-potency topical corticosteroids (eg, clobetasol propionate cream) have been used in the past for small, superficial hemangiomas at risk for ulceration or small periocular lesions [14]. They are now infrequently used since the introduction of topical timolol. In the author’s experience, topical corticosteroids may be helpful for the treatment of minor but recurrent ulcerations. Adverse effects of long-term use of topical corticosteroids include skin atrophy, hypopigmentation, and hypertrichosis.

The use of intralesional corticosteroids such as triamcinolone acetonide 10 to 40 mg/mL is limited to small, well-localized, deep hemangiomas [15]. Individual doses should not exceed 3 mg/kg. A response usually is noted within two weeks, with continued response over the ensuing six to eight weeks [16]. Serial injections administered at four-week intervals are sometimes needed. Adverse effects of intralesional corticosteroids most commonly include local skin atrophy from leaks or inadvertent application to normal surrounding skin. Adrenal suppression from systemic absorption is also a possibility, even with localized use [17-19].

Imiquimod — Imiquimod is a topical immune response modifier with antiangiogenic and pro-apoptotic properties [20]. There are no randomized trials evaluating the efficacy of imiquimod for the treatment of infantile hemangiomas, and results from observational studies and case reports are conflicting [21-25].

In a retrospective chart review of 18 children with 22 hemangiomas, treatment with imiquimod led to the diminution of all 12 superficial hemangiomas, with a mean percentage decrease in size of 60 percent, including four cases of complete clearance [26]. Mixed hemangiomas and deep hemangiomas exhibited a mean percentage decrease in size of 22 percent and 12 percent, respectively.

In contrast, a phase-II, open-label study of imiquimod for superficial and mixed infantile hemangiomas revealed no changes in lesion area, volume, elevation, depth, blood flow, or vessel density after 16 weeks of treatment [21]. Side effects of imiquimod therapy for infantile hemangiomas include local inflammation, crusting, and secondary staphylococcal infections.

Until further studies are available, the decision to prescribe imiquimod should be carefully weighed against active nonintervention and other treatment options for individual patients [27].

COMPLICATED HEMANGIOMAS — Complicated hemangiomas that require treatment include large hemangiomas at increased risk of scarring or disfigurement (eg, large or segmental hemangiomas, facial hemangiomas), life-threatening hemangiomas (eg, airway hemangiomas), hemangiomas carrying functional risks (eg, periocular hemangiomas), or hemangiomas with severe ulceration. (See 'Special situations' below.)

Propranolol — Propranolol, a nonselective beta blocker, is the first-line agent for hemangiomas with the potential to impair function or cause permanent disfigurement, if there are no cardiac or neurovascular concerns [1,28]. In 2014, propranolol hydrochloride oral solution was approved by the US Food and Drug Administration for the treatment of proliferating infantile hemangioma requiring systemic therapy [29].

Propranolol inhibits the growth and induces the regression of infantile hemangiomas [30]. Potential mechanisms of action for propranolol may include vasoconstriction, decreased expression of vascular endothelial growth factor and basic fibroblast growth factor, and/or triggering of apoptosis [31,32].

Efficacy — In 2008, the serendipitous observation that the use of propranolol to treat heart failure in two young children with infantile hemangiomas was associated with a change in color, softening, and decrease in size of the hemangiomas led to the initiation of larger observational studies and randomized trials. All studies demonstrated improvement with propranolol [30,33-39].

In a large, industry-sponsored, randomized trial, 456 infants aged five weeks to five months with a proliferating hemangioma of at least 1.5 cm received placebo or propranolol (1 mg/kg per day or 3 mg/kg per day) for three or six months [39]. The primary outcome was complete or nearly complete resolution of the hemangioma at week 24, assessed by centralized blinded evaluation of digital photographs. Complete or nearly complete resolution of the target hemangioma was observed in 60 percent of patients treated with propranolol 3 mg/kg per day for six months and 4 percent of those treated with placebo. Ten percent of patients in whom treatment was successful required systemic retreatment during follow-up. Mild adverse effects, including diarrhea, sleep disorders, bronchial hyperreactivity, cold extremities, upper respiratory tract infection, and fever, occurred in over 90 percent of patients receiving propranolol and 76 percent of those receiving placebo. Serious adverse events suspected to be related to propranolol were rare (occurred in single patients only) and included second-degree atrioventricular block, bronchiolitis, hemangioma worsening/ulceration, and bradycardia.

A network meta-analysis of 18 randomized trials and cohort studies including 1265 children aged two weeks to nine years evaluated the relative expected rates of clearance associated with beta blockers and corticosteroids [40]. Oral propranolol in doses ranging from 1 to 4 mg/kg per day had the largest mean estimate of expected clearance (95 percent, 95% Bayesian credible interval [BCI] 88-99), relative to oral corticosteroids (43 percent, 95% BCI 21-66) and placebo or observation (6 percent, 95% BCI 1-11).

Oral propranolol has also been used to treat infantile hemangiomas beyond the proliferative phase [41,42]. In a multicentric, retrospective study, 42 children aged 7 months to 10 years with documented cessation of hemangioma growth were treated with propranolol 1.5 to 3 mg/kg per day for one to eight months [41]. In all children, the rate of involution increased with propranolol compared with the rate of involution during active nonintervention before treatment.  

Pretreatment evaluation — Treatment with propranolol should be undertaken in consultation with a pediatric dermatologist or other specialist with expertise in the diagnosis and treatment of pediatric vascular tumors and use of propranolol in children. The pretreatment evaluation (inpatient or outpatient) should include:

History, with focus on cardiovascular and respiratory abnormalities (eg, poor feeding, dyspnea, tachypnea, diaphoresis, wheezing, heart murmur) and family history of heart block or arrhythmia.

Physical examination including cardiac and pulmonary assessment and measurement of heart rate and blood pressure. However, since obtaining accurate blood pressure readings in infants is difficult, blood pressure measurement should be attempted only if there is suspicion of underlying cardiovascular disease. (See "The pediatric physical examination: General principles and standard measurements", section on 'Vital signs'.)

Electrocardiogram (ECG), in children with:

Heart rate lower than normal for age

History of arrhythmia or arrhythmia detected during examination

Family history of congenital heart disease or maternal history of connective tissue disease

Contraindications — Propranolol treatment is contraindicated in infants and children with:

Cardiogenic shock

Documented chronic and significant sinus bradycardia

Documented chronic and significant hypotension

Greater than first-degree heart block

Heart failure


Hypersensitivity to propranolol

Initiation of treatment and dosing — In most cases, treatment can be initiated in an outpatient clinical setting by a clinician with experience in the diagnosis and management of infantile hemangiomas. Every dose increase should also be administered by an experienced clinician in an outpatient setting. However, in accord with an expert consensus panel, we suggest that hospitalization for initiation of oral propranolol be considered in the following circumstances [28]:

Infants ≤8 weeks of age

Preterm infants <48 weeks of postconceptional age

Infants of any age with inadequate social support

Infants of any age with comorbid conditions affecting the cardiovascular or respiratory system, including symptomatic airway hemangiomas

Infants of any age with conditions affecting blood glucose maintenance

We generally start treatment with oral propranolol at 0.5 to 1 mg/kg per day in two or three divided doses with feeds. If tolerated, the dose is then gradually increased (ie, in increments of 0.5 mg/kg per day) over one to two weeks to the target dose of 2 mg/kg per day, given in two or three divided doses with feeds.

Administering propranolol with feeds reduces the risk of hypoglycemia. In case of intercurrent illness associated with vomiting, diarrhea, and/or poor feeding, treatment may be temporarily held and then resumed at a lower dose. (See 'Adverse effects' below.)  

Monitoring — Since the effect of oral propranolol peaks at one to three hours after administration, an expert consensus panel has recommended that patients be monitored with measurement of heart rate and blood pressure at one and two hours after the initial dose and after every dose increase of 0.5 mg/kg/day [28].

Parents should be educated about recognizing signs of serious adverse effects, which include hypotension, bradycardia, wheezing, and hypoglycemia. Early clinical signs of hypoglycemia include sweating, shakiness, tachycardia, anxiety, and hunger, all of which may be masked by beta blockers except sweating. Thus, sweating may be the most reliable early sign of hypoglycemia to watch for.

Routine screening of serum glucose is not indicated, because the timing of hypoglycemic events is variable and unpredictable. In addition, asymptomatic hypoglycemia was not detected in studies that included a random serum glucose as part of routine monitoring [28].

(See "The pediatric physical examination: General principles and standard measurements", section on 'Heart rate'.)

(See "The pediatric physical examination: General principles and standard measurements", section on 'Blood pressure'.)

(See "Evaluation and diagnosis of hypertension in infants between one month and one year of age", section on 'Blood pressure measurement'.)

Assessment of response and treatment duration — Children with infantile hemangiomas treated with propranolol should be followed up at one-month intervals for response assessment and dose adjustment for weight gain. The duration of treatment typically ranges between 6 to 12 months, but may be longer, depending upon the size and location of the hemangioma and response to treatment.

Although a significant response (reduction in size or nearly complete resolution) is generally seen after three to four months of propranolol treatment, some experts continue therapy until the child reaches the age in which the spontaneous involution phase would normally begin [1]. This typically occurs around one year of age, but may occur earlier or later depending on the hemangioma size.

Lack of response to treatment with propranolol is rare. In a French retrospective, multicenter study including 1130 children treated with propranolol, 10 (0.9 percent) had propranolol-resistant hemangiomas [43]. Resistance was defined as continued growth during the proliferative phase or no involution during the post-proliferative stage after >4 weeks of oral propranolol at >2 mg/kg per day. Five of the 10 children who did not respond to propranolol had hemangiomas in the post-proliferative stage and were older than eight months at the start of treatment. Three children with hemangiomas in the proliferative stage showed a rapid response to adjuvant systemic corticosteroids.

Rebound growth — Rebound growth after propranolol discontinuation has been noted in approximately 14 to 25 percent of children [44-46]. The factors associated with the risk of relapse are not completely understood.

Some children with rebound growth may need a second course of propranolol. Topical beta blockers may be used to treat mild to moderate relapses. However, in most cases mild relapses do not require treatment and parents can be reassured about the eventual involution of the lesion.  

In a single-institution study including 158 children with hemangiomas located predominantly in the head and neck region who were treated with propranolol for 3 to 12 months, a relapse occurred in 40 (25 percent) 0.5 to 5 months after treatment cessation [46]. In half of them, the relapse was mild and did not require retreatment. Factors associated with an increased risk of relapse included segmental distribution and depth of the hemangioma.

Adverse effects — Serious adverse effects of propranolol therapy for hemangiomas, which include hypotension, bradycardia, hyperkalemia, bronchospasm, and hypoglycemia, are infrequent [39,47,48]. Restless sleep, constipation or diarrhea, and cold extremities are more commonly reported [48]. Thus, children treated with this drug should be closely monitored.

In a review of 906 French children (median age 114 days) treated with propranolol for complicated hemangiomas, one or more adverse reactions occurred in 81 (9 percent) [49]. Serious adverse effects occurred in 24 patients (2.6 percent) and included cardiac adverse events in two patients, respiratory adverse events in nine, and hypoglycemia in four. Common adverse effects included sleep disturbances, acrocyanosis, and diarrhea.

Of the potential serious adverse effects, hypoglycemia is the most worrisome. To reduce this risk, propranolol should be administered during the daytime hours with a feeding shortly before or after administration. Propranolol should be discontinued during periods of illness or poor oral intake [28,50].

Patients who may be at increased risk for propranolol-induced hypoglycemia include children under the age of one year (especially low-birth-weight infants), patients who were previously treated with prolonged courses of systemic glucocorticoids, and patients with high-output cardiac failure secondary to a large liver hemangioma [50,51]. However, symptomatic hypoglycemia during propranolol use has also been reported in older children [50].

Other beta blockers — A few small trials suggest that nadolol and atenolol may be as effective as propranolol for the treatment of proliferative hemangiomas, potentially with a lower rate of adverse effects such as bronchoreactivity and sleep disturbances [52,53]. However, these findings are preliminary and need to be confirmed by larger trials.

Systemic corticosteroids — Treatment with systemic corticosteroids for complicated hemangiomas has been largely supplanted by systemic beta blockers. However, systemic corticosteroids remain a treatment option for patients with complicated hemangiomas for whom treatment with beta blockers is contraindicated. (See 'Contraindications' above.)

The usual starting dose for prednisolone is 2 to 3 mg/kg per day, although some clinicians advocate higher starting doses of up to 5 to 6 mg/kg per day. A single, morning dose is preferred to minimize adrenal suppression. A response (stabilization±regression) is usually seen within the first few weeks [54,55]. Treatment is generally continued for several months or more, depending upon the indications for treatment, the response, and the child's age at initiation [9]. Prednisone should be slowly discontinued since abrupt discontinuation or rapid tapering of glucocorticoids while a hemangioma is still in its active growth phase may result in rebound proliferation [8].

Adverse effects of systemic corticosteroids are more likely to develop with higher doses and courses of six months or longer and resolve with drug tapering.

The most common complication is the development of a cushingoid facies, which usually begins within the first one to two months of treatment [56].

Personality changes (eg, depressed mood, agitation, insomnia, restlessness) develop in approximately one-third of infants, usually during the first two weeks of therapy [56].

Delayed skeletal growth, which may be more readily apparent since a child grows most rapidly during the first year of life, results from a temporary inhibition of collagen synthesis. However, nearly all children catch up to the normal growth curve once therapy has been discontinued, usually by two years of age [56,57].

Gastric upset occurs in at least 20 percent of infants and can be relieved with histamine 2 (H2) blockers, such as ranitidine hydrochloride, which many initiate routinely along with glucocorticoids [56].

Serious corticosteroid complications, such as aseptic necrosis of the femoral head, hypertension, osteoporosis, and cataracts, are extremely rare in children [56].

Systemic corticosteroids have immunosuppressive effects and can increase the risk for infections [58]. There are at least two reports of Pneumocystis carinii pneumonia (PCP, but officially renamed Pneumocystis jirovecii pneumonia) developing in infants treated with glucocorticoids for hemangiomas [59,60]. While the true risk of PCP and the utility of antibiotic prophylaxis in this population are not known, some advocate that trimethoprim-sulfamethoxazole prophylaxis be considered [58], particularly in infants with airway involvement or other risk factors for PCP [59].

We do not routinely administer PCP prophylaxis to children being treated with systemic glucocorticoids for infantile hemangiomas. However, PCP prophylaxis may be warranted in infants who have other risk factors for PCP (eg, premature infants with significant concomitant medical problems). (See "Glucocorticoid effects on the immune system" and "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in HIV-uninfected patients".)

Live-virus vaccines (eg, measles, mumps, rubella [MMR], varicella, rotavirus), should not be administered while infants are taking supraphysiologic glucocorticoid doses. In addition, because the varicella vaccine is not administered until children are at least one year of age, infants receiving glucocorticoid therapy should avoid exposure to individuals with varicella infection. (See "Standard immunizations for children and adolescents", section on 'Overview'.)

Immunization for diphtheria and tetanus may not be effective in some patients when administered during systemic glucocorticoid therapy [58]. Diphtheria and tetanus titers can be used to confirm protection.

Supraphysiologic doses of glucocorticoids may suppress the hypothalamic-pituitary-adrenal axis. "Stress doses" of glucocorticoids may be necessary for infants who require medical or surgical hospitalization while undergoing glucocorticoid therapy for infantile hemangiomas [61].

Other systemic therapies — Vincristine and interferon alpha are alternative systemic agents for the treatment of complicated hemangiomas but are rarely used since the advent of propranolol.

Vincristine – Vincristine is used in the treatment of the Kasabach-Merritt phenomenon associated with the kaposiform hemangioendothelioma and tufted angioma [62,63] (see "Tufted angioma, kaposiform hemangioendothelioma, and the Kasabach-Merritt phenomenon"). Its use has expanded to include more aggressive hemangiomas as an alternative therapy for life-threatening or severely life-altering hemangiomas unresponsive to propranolol or corticosteroids.

Vincristine is generally administered by a central venous catheter. Its administration is commonly overseen by a pediatric hematologist/oncologist [64-66]. Toxicities of vincristine include peripheral neuropathy, constipation, jaw pain, and rarely leukopenia and anemia.

Interferon alpha – Interferon alpha, a potent inhibitor of angiogenesis, has been used in the past as an alternative therapy for aggressive hemangiomas not responsive to glucocorticoids [4,67-69]. The initial dose of interferon alpha is 3 million units/m2 per day [3]. The interval between administration and response ranges from a few weeks to several months [9].

Adverse effects of interferon alpha that are usually transient include fever, irritability, neutropenia, and liver enzyme abnormalities [54]. The most worrisome adverse effect of interferon is severe neurotoxicity, including spastic diplegia.

In one meta-analysis including 441 infants with vascular lesions treated with interferon, 11 (2.5 percent) developed permanent spastic diplegia and 16 (3.6 percent) motor developmental complications that reversed upon discontinuation of therapy [70]. Because of this concerning adverse effect, interferon alpha is rarely used for the treatment of infantile hemangiomas.

Surgical therapies — When a hemangioma poses primarily cosmetic concerns, therapeutic intervention must be tailored on an individual basis. In addition to systemic, topical, and intralesional medications, therapeutic options include laser therapy and surgery. Cautery, irradiation, and cryotherapy may produce more scarring than untreated lesions and are thus not generally recommended.

Pulsed-dye laser — The pulsed-dye laser (PDL) cannot be expected to affect hemangiomas with deep involvement, since the depth of laser penetration is only 1.2 mm. The most accepted use of PDL in the management of hemangiomas is the treatment of ulceration, post-involution erythema, and/or telangiectasias [4]. Which hemangiomas benefit most from laser therapy and what the optimal settings are remain areas of controversy [71]. Indications, efficacy, and adverse effects of PDL therapy for infantile hemangiomas are discussed in detail elsewhere. (See "Laser and light therapy for cutaneous vascular lesions", section on 'Infantile hemangiomas'.)

Excisional surgery — Surgical excision is often reserved for involuted lesions with residual scars or loose skin; hemangiomas no longer involuting after age four; pedunculated cutaneous hemangiomas (because of the risk of scarring); small, localized periorbital hemangiomas; and slowly involuting lesions in cosmetically concerning locations [54,72,73]. Excisional surgery may also be considered for large periocular hemangiomas, refractory ulcerated hemangiomas, and nasal-tip hemangiomas, but only if medical therapy is thought to pose a greater risk and the resultant scar is likely to be acceptable. In cases without complication, but for which there is uncertainty about the outcome, the benefits and risks of surgical intervention must be carefully considered since the surgical scar may be worse than the results of spontaneous involution [55,74].

Embolization — As a last resort, large visceral (especially hepatic) hemangiomas have been treated with arterial embolization after failure of medical therapy [72]. The results may be temporary.


Periocular hemangiomas — Periocular hemangiomas can compromise vision and cause amblyopia, astigmatism, or strabismus. These hemangiomas should be evaluated by an ophthalmologist experienced with hemangiomas and their treatment [16]. Recommendations may include patching the unaffected eye to ensure that the partially obstructed eye is used. Superficial periocular hemangiomas have been successfully treated with topical beta blockers [10,75]. Surgical excision also may be an option for small, localized lesions [76-79].

Vision-threatening cases are generally treated systemically with propranolol or, less commonly, with intralesional corticosteroids [15,34,80-83]. Intralesional corticosteroids should be managed by a specialist, most often an ophthalmologist with knowledge and experience in this area. Rare but serious side effects, including eyelid necrosis, central retinal artery occlusion, and adrenal suppression, have been reported [84-88].

Ulcerated hemangiomas

Wound care — Gentle and meticulous local wound care is the mainstay of ulcer therapy and is particularly important for lesions in locations subject to trauma and infection, such as the perineum (picture 3). Local wound care reduces pain and helps to prevent secondary infection [89]. Commonly used therapies include topical antibiotics, barrier creams, and non-stick dressings [90]. Very gentle debridement of crusted wounds with saline soaks two to three times daily may also be helpful since crusting prevents re-epithelization and favors infection.

There are a few reports of successful use of topical timolol for the treatment of ulcerated hemangiomas [91-94]. In one retrospective analysis of 30 children with hemangiomas with focal to 3 cm ulcerations predominantly located in intertriginous areas, treatment with one drop per day of timolol 0.5% gel led to ulcer resolution after an average of 67 days [94].  

Topical metronidazole gel, often used in combination with topical mupirocin, has proved to be safe and efficacious for ulceration, particularly in intertriginous or moist areas such as the lip and perineum [89]. When clinically indicated, broad-spectrum oral antibiotics are also occasionally used.

Becaplermin, a synthetic form of platelet-derived growth factor, is approved by the US Food and Drug Administration for treatment of lower-extremity diabetic neuropathic ulcers. It has been reported to be effective as a second-line topical therapy in the treatment of ulcerated hemangiomas that are refractory to standard care [95,96]. Becaplermin prescribing information contains a boxed warning about the possible risk of death from cancer in patients who receive repeated treatment with becaplermin [97]. The studies that prompted the warning were performed in adult patients with diabetes. No cases of cancer have been reported in children who were treated with becaplermin for hemangioma ulceration.

Oral propranolol — We suggest oral propranolol in addition to meticulous wound care and appropriate analgesia for the treatment of ulcerated hemangiomas that may cause permanent disfigurement; interfere with daily life activities (eg, diaper changes, bathing, feeding, sleeping); or are unresponsive to wound care and pain and infection control. (See 'Propranolol' above.)

A beneficial effect of propranolol on ulcerated hemangiomas has been reported in several case series [98-101].

In two studies, treatment with oral propranolol (2 to 2.5 mg/kg per day) was associated with a shorter time to pain control and healing (mean time to healing of 4.3 and 8.7 weeks compared with 22.4 weeks in a group of historical controls treated only with supportive measures) [98,99].

In another study, 64 infants with ulcerated hemangiomas of the head and neck region were treated with oral propranolol 2 mg/kg per day in three divided doses or a combination of ibuprofen 10 mg/kg and paracetamol 16.2 mg/kg every eight hours for up to six months [102]. A complete or partial response was achieved in 24 of 28 patients in the propranolol group and in 12 of 24 patients in the ibuprofen/paracetamol group, with a mean time to healing of 18 and 28 days, respectively.

Analgesia — The pain associated with ulceration can be severe. Affected infants commonly suffer from sleep disturbance and increased irritability. Use of oral acetaminophen (with or without codeine) or a topical anesthetic agent (ie, lidocaine hydrochloride 2 to 5% ointment) may be warranted. To avoid the risk of lidocaine toxicity, parents should be instructed to apply only a pea-sized amount of lidocaine to the affected area no more than four times per day.

Eutectic mixture of local anesthetics (EMLA) should be avoided in infants less than three months of age because it contains prilocaine hydrochloride, which has been associated with infantile methemoglobinemia. Infants younger than three months have low levels of methemoglobin reductase. The risk of methemoglobinemia is increased when EMLA is used concomitantly with other methemoglobinemia-associated drugs (table 1). (See "Genetics and pathogenesis of methemoglobinemia", section on 'Infants and children'.)

Pulsed-dye laser — Pulsed-dye laser (PDL) 595 nm can be used as an adjunctive treatment for ulcerated hemangiomas that fail to heal after medical therapy and optimal wound care [1]. Treatment can be repeated at two- to four-week intervals. (See "Laser and light therapy for cutaneous vascular lesions", section on 'Infantile hemangiomas'.)

Airway hemangiomas — Because of the small caliber of the infant airway, a growing airway hemangioma can lead to life-threatening airway obstruction. (See "Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications", section on 'Airway hemangiomas'.)

Systemic propranolol is generally the first line of therapy for children with symptomatic airway hemangiomas [33,103]. Laser ablation is an occasional second-line therapy [104]. Rarely, tracheotomy may be required.

In a multicenter study, 27 infants aged one to five months with airway hemangiomas were treated with oral propranolol 2 mg/kg per day for a median time of 15 months (range 7 to 34 months) [105]. Eleven children were treated with propranolol alone, whereas 16 received intralesional corticosteroid injection at the time of propranolol initiation. The symptoms of stridor generally resolved within a day of initiation of propranolol treatment. However, additional therapy, including systemic steroids, laser ablation, or surgical excision, was required in 16 children because of recurrence of respiratory symptoms.

High-output failure — Infants with significant hepatic or very large cutaneous hemangiomas may rarely develop high-output heart failure within the first several months of life. Treatment in such cases may include: systemic propranolol and/or glucocorticoids; vincristine or interferon in unresponsive, life-threatening cases; hepatic arterial embolization in selected hepatic cases; and/or treatment of heart failure (with fluid restriction, diuretics, and digoxin as indicated) [106].

PHACE syndrome — The presence of severe arterial anomalies may restrict the use of propranolol in some patients with PHACE syndrome (MIM 606519) [107]. In addition to large facial hemangiomas, patients with this disorder exhibit coarctation of the aorta and abnormalities of the cerebral and cervical vasculature and vessels of the aortic arch. It is known that a small percentage of patients with severe cerebral or cervical anomalies develop acute arterial ischemic stroke, most often during infancy or toddlerhood [108]. Thus, there is at least theoretical concern that propranolol-induced hypotension and reduced cerebrovascular perfusion in patients with already compromised cerebral vasculature could increase the risk of stroke in this population [107]. (See "Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications", section on 'PHACE syndrome'.)

Consensus guidelines recommend that infants with PHACE syndrome be thoroughly evaluated with magnetic resonance imaging/magnetic resonance angiography (MRI/MRA) of the head and neck and cardiac imaging to include the aortic arch before starting propranolol treatment [28]. MRA findings that confer the highest risk of stroke include severe, long-segment narrowing or nonvisualization of major head or neck arteries without adequate collateral/compensatory circulation, especially in the presence of concomitant cardiac and aortic arch anomalies [108].

The risks and benefits of propranolol treatment for patients with PHACE syndrome who have high-risk MRA features should be discussed in consultation with neurology and/or cardiology specialists [28]. If the potential benefits of propranolol treatment are deemed to outweigh the risks, propranolol should be given at the lowest possible dose, with slow upward dose titration and three-times-daily dosing [28]. This schedule is aimed at minimizing abrupt changes in systolic blood pressure, which is a known risk factor for stroke.

In a retrospective study, 32 children with PHACE syndrome were successfully treated with propranolol at the average dose of 1.8 mg/kg per day [109]. One patient experienced mild right-side hemiparesis, and two had soft tissue effects (eg, worsening of ulceration, acrocyanosis, nail dystrophy, small digital infarcts). Although no severe neurologic events were reported in this large case series, the possibility that propranolol augments the potential risk of stroke in this population cannot be ignored.

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topic (see "Patient information: Hemangioma (The Basics)")


The approach to the treatment and the choice of treatment modality for infantile hemangiomas should be individualized depending upon the size of the lesion(s), location, presence of complications, potential for scarring or disfigurement, the age of the patient, the rate of growth or involution at the time of evaluation, the potential risk(s) and benefits of treatment, the availability of the various modalities, and the experience of the treating clinician. (See 'General approach' above.)

Treatment is usually required for complicated hemangiomas that may interfere with a vital structure or function and for lesions at increased risk of ulceration, scarring, and disfigurement. The goals of treatment include prevention or reversal of life- or function-threatening complications; prevention or minimization of disfigurement, bleeding, infection, and pain; and minimization of psychosocial distress for the patient and family. (See 'Indications for intervention and goals of treatment' above.)

We suggest active nonintervention for uncomplicated hemangiomas that are not disfiguring (Grade 2C). Active nonintervention requires regular monitoring of the clinical course and attention to the psychosocial implications for the child and family. (See 'Active nonintervention' above.)

We recommend oral propranolol as the first-line agent for the treatment of complicated hemangiomas with the potential to impair function or cause disfigurement (eg, periorbital hemangiomas) (Grade 1A). Treatment is started with 0.5 to 1 mg/kg per day and then gradually increased to the target dose of 2 mg/kg per day. (See 'Propranolol' above.)

Systemic glucocorticoids, vincristine, and interferon alpha are alternative agents for aggressive hemangiomas but are rarely needed since the advent of propranolol. (See 'Systemic corticosteroids' above and 'Other systemic therapies' above.)

Children with periorbital hemangiomas should be evaluated by an ophthalmologist who is experienced in the treatment of hemangiomas. (See 'Periocular hemangiomas' above.)

We suggest oral propranolol in addition to meticulous wound care and appropriate analgesia for the treatment of ulcerated hemangiomas that may cause permanent disfigurement, interfere with daily life activities, or do not respond to wound care measures (Grade 2C). (See 'Ulcerated hemangiomas' above.)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and Management of Infantile Hemangioma. Pediatrics 2015; 136:e1060.
  2. Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and Management of Infantile Hemangioma: Executive Summary. Pediatrics 2015; 136:786.
  3. Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997; 37:631.
  4. Frieden IJ. Which hemangiomas to treat--and how? Arch Dermatol 1997; 133:1593.
  5. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122:360.
  6. Garzon M. Infantile hemangiomas. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier Limited, Spain 2008. p.1565.
  7. Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics 1998; 101:446.
  8. Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000; 136:905.
  9. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999; 341:173.
  10. Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128:255.
  11. Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010; 146:564.
  12. Blatt J, Morrell DS, Buck S, et al. β-blockers for infantile hemangiomas: a single-institution experience. Clin Pediatr (Phila) 2011; 50:757.
  13. Ovadia SA, Landy DC, Cohen ER, et al. Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis. Ann Plast Surg 2015; 74:256.
  14. Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 2005; 52:281.
  15. Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg 2000; 35:420.
  16. Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol 2004; 21:1.
  17. Mills CM, Marks R. Side effects of topical glucocorticoids. Curr Probl Dermatol 1993; 21:122.
  18. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998; 38:318.
  19. Olsen EA, Cornell RC. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol 1986; 15:246.
  20. Schön M, Schön MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem 2007; 14:681.
  21. McCuaig CC, Dubois J, Powell J, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol 2009; 26:203.
  22. Senchak AJ, Dann M, Cable B, Bessinger G. Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5%: a report of 3 cases. Ear Nose Throat J 2010; 89:E21.
  23. Qiu Y, Ma G, Lin X, et al. Treating protruding infantile hemangiomas with topical imiquimod 5% cream caused severe local reactions and disfiguring scars. Pediatr Dermatol 2013; 30:342.
  24. Barry RB, Hughes BR, Cook LJ. Involution of infantile haemangiomas after imiquimod 5% cream. Clin Exp Dermatol 2008; 33:446.
  25. Welsh O, Olazarán Z, Gómez M, et al. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004; 51:639.
  26. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 2007; 56:63.
  27. Czernik A, Bystryn JC. Does imiquimod work in infantile hemangiomas? J Am Acad Dermatol 2007; 57:535; author reply 536.
  28. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131:128.
  29. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf (Accessed on March 30, 2016).
  30. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358:2649.
  31. Ozeki M, Nozawa A, Hori T, et al. Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor. Pediatr Int 2016.
  32. Kum JJ, Khan ZA. Mechanisms of propranolol action in infantile hemangioma. Dermatoendocrinol 2014; 6:e979699.
  33. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128:e259.
  34. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009; 124:e423.
  35. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope 2009; 119:2051.
  36. Denoyelle F, Leboulanger N, Enjolras O, et al. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol 2009; 73:1168.
  37. Theletsane T, Redfern A, Raynham O, et al. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol 2009; 23:1465.
  38. Truong MT, Chang KW, Berk DR, et al. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010; 156:335.
  39. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372:735.
  40. Chinnadurai S, Fonnesbeck C, Snyder KM, et al. Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis. Pediatrics 2016; 137:e20153896.
  41. Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol 2011; 28:94.
  42. Vivas-Colmenares GV, Bernabeu-Wittel J, Alonso-Arroyo V, et al. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase. Pediatr Dermatol 2015; 32:348.
  43. Caussé S, Aubert H, Saint-Jean M, et al. Propranolol-resistant infantile haemangiomas. Br J Dermatol 2013; 169:125.
  44. Shah SD, Baselga E, McCuaig C, et al. Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. Pediatrics 2016; 137.
  45. Wedgeworth E, Glover M, Irvine AD, et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. Br J Dermatol 2016; 174:594.
  46. Ahogo CK, Ezzedine K, Prey S, et al. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. Br J Dermatol 2013; 169:1252.
  47. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009; 26:610.
  48. de Graaf M, Breur JM, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol 2011; 65:320.
  49. Prey S, Voisard JJ, Delarue A, et al. Safety of Propranolol Therapy for Severe Infantile Hemangioma. JAMA 2016; 315:413.
  50. Holland KE, Frieden IJ, Frommelt PC, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010; 146:775.
  51. Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol 2011; 28:169.
  52. Pope E, Chakkittakandiyil A, Lara-Corrales I, et al. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol 2013; 168:222.
  53. Ábarzúa-Araya A, Navarrete-Dechent CP, Heusser F, et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol 2014; 70:1045.
  54. Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001; 27:475.
  55. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg 2000; 37:517.
  56. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104:1616.
  57. Lomenick JP, Backeljauw PF, Lucky AW. Growth, bone mineral accretion, and adrenal function in glucocorticoid-treated infants with hemangiomas-- a retrospective study. Pediatr Dermatol 2006; 23:169.
  58. Kelly ME, Juern AM, Grossman WJ, et al. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol 2010; 146:767.
  59. Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc 2004; 79:243.
  60. Maronn ML, Corden T, Drolet BA. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol 2007; 143:1224.
  61. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004; 140:963.
  62. Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002; 24:459.
  63. Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, et al. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2013; 60:1478.
  64. Perez J, Pardo J, Gomez C. Vincristine--an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol 2002; 41:197.
  65. Fawcett SL, Grant I, Hall PN, et al. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 2004; 57:168.
  66. Moore J, Lee M, Garzon M, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg 2001; 36:1273.
  67. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326:1456.
  68. Jiménez-Hernández E, Dueñas-González MT, Quintero-Curiel JL, et al. Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. Dermatol Surg 2008; 34:640.
  69. Chao YH, Liang DC, Chen SH, et al. Interferon-alpha for alarming hemangiomas in infants: experience of a single institution. Pediatr Int 2009; 51:469.
  70. Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004; 114:1231.
  71. Stier MF, Glick SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. J Am Acad Dermatol 2008; 58:261.
  72. Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10:311.
  73. Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg 2012; 130:619.
  74. McHeik JN, Renauld V, Duport G, et al. Surgical treatment of haemangioma in infants. Br J Plast Surg 2005; 58:1067.
  75. Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol 2011; 129:377.
  76. Slaughter K, Sullivan T, Boulton J, et al. Early surgical intervention as definitive treatment for ocular adnexal capillary haemangioma. Clin Experiment Ophthalmol 2003; 31:418.
  77. Schneider D, Lee MS, Harrison AR, Sidman J. Excision of periorbital hemangiomas to correct visual abnormalities. Arch Facial Plast Surg 2011; 13:195.
  78. Frank RC, Cowan BJ, Harrop AR, et al. Visual development in infants: visual complications of periocular haemangiomas. J Plast Reconstr Aesthet Surg 2010; 63:1.
  79. Claude O, Picard A, O'Sullivan N, et al. Use of ultrasonic dissection in the early surgical management of periorbital haemangiomas. J Plast Reconstr Aesthet Surg 2008; 61:1479.
  80. Taban M, Goldberg RA. Propranolol for orbital hemangioma. Ophthalmology 2010; 117:195.
  81. Fay A, Nguyen J, Jakobiec FA, et al. Propranolol for isolated orbital infantile hemangioma. Arch Ophthalmol 2010; 128:256.
  82. Al Dhaybi R, Superstein R, Milet A, et al. Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. Ophthalmology 2011; 118:1184.
  83. Janmohamed SR, Madern GC, Nieuwenhuis K, et al. Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy: still an alternative besides propranolol. Pediatr Surg Int 2012; 28:393.
  84. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986; 17:229.
  85. Weiss AH. Adrenal suppression after corticosteroid injection of periocular hemangiomas. Am J Ophthalmol 1989; 107:518.
  86. Glatt HJ, Putterman AM, Van Aalst JJ, Levine MR. Adrenal suppression and growth retardation after injection of periocular capillary hemangioma with corticosteroids. Ophthalmic Surg 1991; 22:95.
  87. Sutula FC, Glover AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg 1987; 18:103.
  88. Goyal R, Watts P, Lane CM, et al. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Ophthalmology 2004; 111:389.
  89. Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001; 44:962.
  90. Morelli JG, Tan OT, Yohn JJ, Weston WL. Treatment of ulcerated hemangiomas infancy. Arch Pediatr Adolesc Med 1994; 148:1104.
  91. Thomas J, Kumar P, Kumar DD. Ulcerated infantile haemangioma of buttock successfully treated with topical timolol. J Cutan Aesthet Surg 2013; 6:168.
  92. Cante V, Pham-Ledard A, Imbert E, et al. First report of topical timolol treatment in primarily ulcerated perineal haemangioma. Arch Dis Child Fetal Neonatal Ed 2012; 97:F155.
  93. Beal BT, Chu MB, Siegfried EC. Ulcerated infantile hemangioma: novel treatment with topical brimonidine-timolol. Pediatr Dermatol 2014; 31:754.
  94. Boos MD, Castelo-Soccio L. Experience with topical timolol maleate for the treatment of ulcerated infantile hemangiomas (IH). J Am Acad Dermatol 2016; 74:567.
  95. Sugarman JL, Mauro TM, Frieden IJ. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol 2002; 138:314.
  96. Metz BJ, Rubenstein MC, Levy ML, Metry DW. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004; 140:867.
  97. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM142821.pdf.
  98. Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011; 64:827.
  99. Hermans DJ, van Beynum IM, Schultze Kool LJ, et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol 2011; 64:833.
  100. Kim LH, Hogeling M, Wargon O, et al. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011; 46:759.
  101. Hong E, Fischer G. Propranolol for recalcitrant ulcerated hemangioma of infancy. Pediatr Dermatol 2012; 29:64.
  102. Tiwari P, Pandey V, Gangopadhyay AN, et al. Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral Maxillofac Surg 2016; 20:73.
  103. Peridis S, Pilgrim G, Athanasopoulos I, Parpounas K. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol 2011; 75:455.
  104. Rahbar R, Nicollas R, Roger G, et al. The biology and management of subglottic hemangioma: past, present, future. Laryngoscope 2004; 114:1880.
  105. Elluru RG, Friess MR, Richter GT, et al. Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas. Otolaryngol Head Neck Surg 2015; 153:452.
  106. Greene AK, Rogers GF, Mulliken JB. Management of parotid hemangioma in 100 children. Plast Reconstr Surg 2004; 113:53.
  107. Metry DW, Garzon MC, Drolet BA, et al. PHACE syndrome: current knowledge, future directions. Pediatr Dermatol 2009; 26:381.
  108. Siegel DH, Tefft KA, Kelly T, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke 2012; 43:1672.
  109. Metry D, Frieden IJ, Hess C, et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol 2013; 30:71.
Topic 5792 Version 29.0

Topic Outline



All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.